Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of Hemay005 in Behçet's disease
CTR20232593Phase 3Active
- Sponsor
- Hemay Pharmaceutical Technology
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mufemilast in Behçet's disease (BD), sponsored by Hemay Pharmaceutical Technology. Started Nov 2023; status: active.
02
Drugs
mufemilast
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on CTR20232593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232593.